-
GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients with Recent Clinical Data for GEO-CM04S1
IDSA’s Recommendations Reinforce GeoVax’s Phase 2 Findings: Robust T-Cell Responses, Cross-Variant Durability, and Favorable Safety Profile in Vulnerable Populations Atlanta, GA — October…
-
GeoVax Comments on U.S. “America First Global Health Strategy” and Highlights Company’s Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security
Pipeline Intersects With the Vast Majority of Strategic Initiatives to Make America Safer, Stronger, and More Prosperous Atlanta, GA – September 29, 2025 –…
-
GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications
Initiative Builds on Checkpoint Inhibitor Momentum and Landmark KEYNOTE-689 Results ATLANTA, GA – September 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a…
-
GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations
Company Underscores Rigorous Safety Monitoring and Long History of the MVA Platform as Development of GEO-CM04S1 Advances Atlanta, GA – September 22, 2025 –…
-
GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
Next-Generation Multi-Antigen COVID-19 Vaccine Demonstrates Differentiated Immune Responses in Immunocompromised Patients ATLANTA, GA, September 18, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage…
-
GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference
Multi-Antigen COVID-19 Vaccine Candidate Outperforms mRNA Comparator; Enrollment Now Limited to GEO-CM04S1 Arm ATLANTA, GA – September 15, 2025 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference
Next-Generation Multi-Antigen COVID-19 Vaccine Demonstrates Strong Immune Responses in High-Need Patient Populations ATLANTA, GA – September 12, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences
GEO-CM04S1 Demonstrates Promise Among Most Vulnerable Immunocompromised Patients ATLANTA, GA, September 8, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing…
-
GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Company to provide key updates on GEO-MVA, GEO-CM04S1, and Gedeptin® programs ATLANTA, GA, September 3, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage…
-
GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit
Company Underscores its Commitment to Advancing Equitable Access to Vaccines and Health Innovation on a Global Stage Atlanta, Georgia – October 1,…
-
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
Expands Intellectual Property Portfolio Supporting Next-Generation COVID-19 Vaccine Candidates ATLANTA, GA, August 20, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing…
-
GeoVax to Present at the Emerging Growth Conference on August 20, 2025
Company to Provide Key Updates on GEO-MVA and Its Mpox Vaccine Development Program ATLANTA, GA, August 18, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX),…